KRAS G12C inhibitor 57

KRAS G12C inhibitor 57 (Compound 50) 是一种有效的、选择性的、共价的和具有口服活性的 KRAS G12C 抑制剂,在 KRAS G12C/SOS1 结合试验中对 KRAS G12C 的 IC50 为 0.21 μM,并可诱导癌细胞凋亡 (apoptosis)。
产品编号: MS-K05460 CAS No.: 2821863-70-9 分子式: C35H38FN7O2 分子量: 607.72
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

KRAS G12C inhibitor 57 (Compound 50) 是一种有效的、选择性的、共价的和具有口服活性的 KRAS G12C 抑制剂,在 KRAS G12C/SOS1 结合试验中对 KRAS G12C 的 IC50 为 0.21 μM,并可诱导癌细胞凋亡 (apoptosis)。

生物实验数据

生物活性 KRAS G12C inhibitor 57 (Compound 50) is a potent, selective, covalent, and orally active KRAS G12C inhibitor with an IC50 of 0.21 μM against KRAS G12C in the KRAS G12C/SOS1 binding assay, and it induces apoptosis in cancer cells.
IC50 & Target

KRAS(G12C)

0.21 μM (IC50, KRAS G12C/SOS1 binding assay)

体外研究
(In Vitro)

KRAS G12C inhibitor 57 (Compound 50) (0-10 μM; 3 days) 对 KRAS 和 KRAS 驱动的细胞系有选择性抑制,以及对下游信号的强烈抑制。
KRAS G12C inhibitor 57 (0.1-1 μM; 24 h) 诱导 H358 细胞凋亡。
KRAS G12C inhibitor 57 (0.1-1 μM; 48 h) 抑制 H358 细胞肿瘤转移。

Western Blot Analysis

Cell Line: H358 (KRAS p. G12C) cells
Concentration: 0, 0.1, 0.3, 0.5, 1 and 5 μM
Incubation Time: 4 and 24 h
Result: Inhibited the active KRAS-GTP and the phosphorylation of ERK and AKT (MAPK and PI3K pathway) in the dose- and time-dependent manners, and strong inhibitory effects on the phosphorylation of ERK at the concentration of 0.1 μM. Increased the cleaved PARP and caspase-7 induction (24 h).

Western Blot Analysis

Cell Line: H1975 cell line
Concentration: 5, 10, and 20 μM
Incubation Time: 4 h
Result: Interrupted the phosphorylation of ERK.

Cell Proliferation Assay

Cell Line: H358 cells harboring KRAS p.G12C, MIA Paca2 cells harboring KRAS p.G12C, H1975 cells harboring KRAS p.WT and A549 cells harboring KRAS p.G12S
Concentration: 0-10 μM
Incubation Time: 3 days
Result: Displayed favourable inhibitory activities on H358 cells and MIA Paca2 cells with the IC50 values of 0.16 μM and 0.87 μM, in sharp contrast with no obvious inhibition on cell proliferation on H1975 cells (IC50 = 7.91 μM) and A549 cells (IC50 = 29.9 μM).

Apoptosis Analysis

Cell Line: H358 cell line
Concentration: 0.1, 0.3, 0.5 and 1 μM
Incubation Time: 24 h
Result: Induced cellular apoptosis in dose-dependent manner.

Cell Migration Assay

Cell Line: H358 cells
Concentration: 0.1, 0.5 and 1 μM
Incubation Time: 48 h
Result: Significantly suppressed the migration.

Cell Invasion Assay

Cell Line: H358 cells
Concentration: 0.1, 0.5 and 1 μM
Incubation Time: 48 h
Result: Inhibited the cellular invasion and exhibited the dose-dependent inhibitory potency.
体内研究
(In Vivo)

KRAS G12C inhibitor 57 (Compound 50) (10 and 30 mg/kg; p.o.; daily for 20 days) 对 H358异种移植模型小鼠有抗肿瘤作用。
Pharmacokinetic data of KRAS G12C inhibitor 57 (Compound 50) in ICR mice.

Parameter iv (3 mg/kg) Parameter po (30 mg/kg)
AUC(0−t) (h*ng/mL) 801 AUC(0−t) (h*ng/mL) 600
AUC(0−∞) (h*ng/mL) 804 AUC(0−∞) (h*ng/mL) 835
C0 (ng/mL) 1964 Cmax (ng/mL) 316
T1/2 (h) 0.930 T1/2 (h) 4.79
Vss (L/kg) 4.98 Tmax (h) 0.083
CL (mL/h/kg) 3739 F (%) 10.4
AUCo‑inf (h*mg/mL) 7060 ± 1020 (14.5%) 21800 ± 2310 (10.6%) 101000 ± 16700 (16.6%)

Animal Model: BALB/c-nu/nu mice, H358 xenograft model
Dosage: 10 mg/kg and 30 mg/kg
Administration: Oral administration, daily for 20 days
Result: Significantly inhibited the tumor growth in a dose-dependent manner with remarkable tumor regression at the dose of 30 mg/kg (tumor growth inhibition, TGI = 84.0%). All dosage groups were well-tolerated with no loss of body weight and no morphological damage to viscera including the heart, spleen, and kidney. Significantly suppressed the phosphorylation of ERK and AKT in tumors of nude mice when dosing orally at 10 mg/kg and 30 mg/kg.
Animal Model: ICR mice
Dosage: 3 mg/kg or 30 mg/kg
Administration: IV or PO (Pharmacokinetic Analysis)
Result: Displayed reasonable clearance and half-life by iv administration. Showed a moderate oral bioavailability (F) of 10.4%.

化学信息

分子量 607.72
分子式 C35H38FN7O2
CAS No. 2821863-70-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础